Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Tissue Sodium in Chronic Heart Failure (ELSI)
NCT03128528Phase 2Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in chronic heart failure (CHF), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Jul 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT03128528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128528.